Research at EpiEndo Pharmaceuticals focuses on finding ways to strengthen epithelial tissues using novel drugs. Based on the existing commercial macrolide azithromycin, we are finding ways to create new treatments for chronic airway diseases, with applications for other epithelial tissues.
The research team at EEP has over a decade´s experience studying the lungs and the effects of the macrolide antibiotic, azithromycin (Asgrimsson et al. 2006. Antimicrobial Agents and Chemotherapy, 50:1805-12., Halldorsson et al. 2007. In Vitro Cell Develop Biol, 43:283-89., Halldorsson et al. 2010. Am J Resp Cell Mol Biol, 42:62-8.). Patients receiving azithromycin showed reduced hospital admissions, and our studies demonstrate that azithromycin could enhance barrier strength at the cellular level.
Our current focus is to develop novel and proprietary drugs that preserve the barrier enhancing effects of azithromycin but lack the antibiotic activity. The cellular response to these new drugs are the key focus, ranging from how they enhance the cellular barrier of the lungs to the response generated by the cells, which contribute to improved lung function.